STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLB
  4. [Form 4] Core Laboratories Inc. /DE/ Insider Trading Activity

Core Laboratories (CLB) director gains restricted stock and 8,069 shares vest

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Core Laboratories director Katherine Murray reported equity compensation activity. She received a grant of 7,895 Restricted Shares that will vest after a one-year period ending on April 1, 2027, subject to issuance terms and an elective deferral. Separately, 8,069 Restricted Shares completed a prior one-year vesting period and converted into 8,069 shares of Common Stock at no cost, bringing her directly held Common Stock to 29,290 shares.

Positive

  • None.

Negative

  • None.
Insider Murray Katherine
Role Director
Type Security Shares Price Value
Grant/Award Restricted Shares 7,895 $0.00 --
Exercise Restricted Shares 8,069 $0.00 --
Exercise Common Stock 8,069 $0.00 --
Holdings After Transaction: Restricted Shares — 7,895 shares (Direct); Common Stock — 29,290 shares (Direct)
Footnotes (1)
  1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.
Restricted Shares granted 7,895 shares New grant vesting after one-year period ending April 1, 2027
Restricted Shares vested 8,069 shares Vested after one-year vesting period ending April 1, 2026
Exercise/Conversion price $0.00 per share Conversion of 8,069 Restricted Shares into Common Stock
Common Stock held after transactions 29,290 shares Directly held by Katherine Murray following the April 1, 2026 activity
New Restricted Shares underlying security 7,895 Common Stock shares Underlying security for newly granted Restricted Shares
Restricted Shares financial
"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period"
Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.
vesting period financial
"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period"
A vesting period is the set amount of time someone must wait before they fully own granted shares, stock options, or other equity tied to their work or an agreement; ownership increases gradually or in steps during that time. Investors care because vesting determines when insiders or employees can sell shares, which affects future supply of stock, company incentives and executive retention—think of it like unlocking ownership over installments rather than receiving it all at once.
deferral election financial
"Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2"
Treasury Regulation 1.409A-2 regulatory
"Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Murray Katherine
(Last)(First)(Middle)
6316 WINDFERN ROAD
(Street)
HOUSTON TEXAS 77040
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/01/2026M8,069A$029,290D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Shares$004/01/2026A7,895 (1) (1)Common Stock7,895$07,895D
Restricted Shares$004/01/2026M8,069 (2) (2)Common Stock8,069$00D
Explanation of Responses:
1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.
2. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.
/s/ Mark Tattoli, Attorney-in-Fact04/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Core Laboratories (CLB) director Katherine Murray report?

Katherine Murray reported routine equity compensation activity. She received 7,895 Restricted Shares and had 8,069 previously granted Restricted Shares vest and convert into Common Stock at no cost, increasing her directly held Common Stock position to 29,290 shares.

How many Core Laboratories (CLB) Restricted Shares were granted to Katherine Murray?

Katherine Murray was granted 7,895 Restricted Shares. These shares are scheduled to vest after a one-year vesting period ending April 1, 2027, subject to the terms of issuance and a deferral election that can delay distribution until after she leaves the Board.

Did Katherine Murray sell any Core Laboratories (CLB) shares in this Form 4 filing?

The filing shows no sales. All transactions are acquisitions: a grant of 7,895 Restricted Shares and the vesting and conversion of 8,069 Restricted Shares into Common Stock, with her directly held Common Stock rising to 29,290 shares following these transactions.

What happened to the 8,069 Restricted Shares reported by Katherine Murray at Core Laboratories (CLB)?

The 8,069 Restricted Shares completed a one-year vesting period ending April 1, 2026. They were exercised or converted at a price of $0.00 per share into 8,069 shares of Common Stock, contributing to Katherine Murray’s total directly held Common Stock position of 29,290 shares.

When will Katherine Murray’s new Core Laboratories (CLB) Restricted Shares vest and be distributed?

The 7,895 newly granted Restricted Shares will vest at the end of a one-year vesting period on April 1, 2027. Under a deferral election, vested shares will be distributed as Common Stock after Katherine Murray’s separation of service from the Core Laboratories Board.

How many Core Laboratories (CLB) Common Stock shares does Katherine Murray hold after these transactions?

After the reported transactions, Katherine Murray directly holds 29,290 shares of Core Laboratories Common Stock. This total reflects the conversion of 8,069 previously restricted shares into Common Stock, in addition to her existing holdings prior to this Form 4 filing.